[Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine].
The paper presented a case of a patient with type III by FAB myelodysplastic syndrome, in whom during a low dose cytarabine therapy ventricular fibrillation occurred. Authors discussed roles of anemia, ischemic heart disease and hypokalemia as factors which could increase circulatory system sensitivity on cytarabine action.
Drzewoski
J
J
Krykowski
E
E
Robak
T
T
Jerzmanowski
P
P
Kusowska
J
J
Koźbiał
H
H
D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000139:chemically induced*
D003561:Cytarabine
Migotanie komór u chorego z zespołem mielodysplastycznym leczonego małymi dawkami cytarabiny.